CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma

Multiple myeloma remains an incurable haematological malignancy, with a significant proportion of patients experiencing relapse and becoming refractory to standard therapies, including proteasome inhibitors, immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies.¹ The evolving treatment landscape necessitates continuous investigation into agents with novel mechanisms of action to overcome resistance and improve survival.² Patients with RRMM often present with high-risk cytogenetics, extramedullary disease, and prior exposure to multiple lines of therapy, underscoring the need for effective, tolerable new options.³

Understanding Emerging CELMoD Research

Cereblon E3 ligase modulators (CELMoDs) represent a new generation of immunomodulatory agents distinct from thalidomide, lenalidomide, and pomalidomide.⁴ These compounds, such as iberdomide and mezigdomide, exhibit enhanced cereblon binding affinity, leading to more potent degradation of Aiolos and Ikaros, key transcription factors involved in myeloma cell survival and proliferation.⁵ This increased degradation results in superior anti-myeloma activity and enhanced T-cell co-stimulation compared to earlier IMiDs.⁶

Early phase clinical trials of CELMoDs in RRMM have demonstrated promising efficacy. For instance, studies of mezigdomide (CC-92480) in heavily pretreated patients, including those refractory to IMiDs, proteasome inhibitors, and anti-CD38 antibodies, have reported objective response rates (ORR) ranging from 30% to 60%, depending on the dose and patient population.⁷ In one Phase 1/2 study, patients receiving mezigdomide monotherapy achieved an ORR of 40% (N=100), with a median duration of response of 7.6 months.⁸ The safety profile generally includes myelosuppression, particularly neutropenia (Grade 3/4 in 50-70% of patients), and gastrointestinal toxicities, which are typically manageable with dose modifications and supportive care.⁹

Iberdomide (CC-220) has similarly shown activity in RRMM. In a Phase 1/2 trial, iberdomide monotherapy achieved an ORR of 26.4% (N=182) in a heavily pretreated population, with a median progression-free survival of 3.7 months.¹⁰ When combined with dexamethasone, the ORR increased to 31.5%.¹¹ Common adverse events included neutropenia (Grade 3/4 in 47% of patients) and infections.¹² These data suggest that CELMoDs can induce responses in patients with limited therapeutic alternatives, including those with triple-class refractory disease.¹³

The ongoing research at ASCO 2026 is expected to provide further insights into optimal dosing, combination strategies, and the long-term efficacy and safety of these agents. Studies are exploring CELMoDs in combination with other anti-myeloma drugs, such as dexamethasone, proteasome inhibitors, and anti-CD38 antibodies, to enhance response rates and overcome resistance mechanisms.¹⁴ The potential for CELMoDs to restore sensitivity to IMiDs in refractory patients is also a key area of investigation.¹⁵

Limitations of current data include the early phase nature of many trials, primarily focusing on heavily pretreated populations, which may not fully represent the broader RRMM patient spectrum. The follow-up duration in some studies remains relatively short, limiting conclusions on long-term survival benefits. Future research will need to address the optimal sequencing of CELMoDs within the treatment paradigm, identify predictive biomarkers for response, and further characterise their safety profiles in larger patient cohorts and in combination regimens.¹⁶